Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
Agilent Technologies's Sloan Ratio for the quarter that ended in Apr. 2026 was 2.45%.
As of Apr. 2026, Agilent Technologies has a Sloan Ratio of 2.45%, indicating the company is in the safe zone and there is no funny business with accruals.
Agilent Technologies (MEX:A) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Apr. 2026, Agilent Technologies has a Sloan Ratio of 2.45%, indicating the company is in the safe zone and there is no funny business with accruals.
Agilent Technologies Sloan Ratio % Related Terms
Agilent Technologies Sloan Ratio % Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Sloan Ratio % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:A vs NTRA, WAT, IDXX: Sloan Ratio % Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Sloan Ratio % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Sloan Ratio % falls into.
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
Agilent Technologies's Sloan Ratio for the fiscal year that ended in Oct. 2025 is calculated as
Agilent Technologies's Net Income for the trailing twelve months (TTM) ended in Apr. 2026 was 6315.792 (Jul. 2025 ) + 8049.181 (Oct. 2025 ) + 5291.537 (Jan. 2026 ) + 5937.958 (Apr. 2026 ) = MXN25,594 Mil.
Agilent Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Apr. 2026 was 6804.514 (Jul. 2025 ) + 10107.843 (Oct. 2025 ) + 4649.612 (Jan. 2026 ) + 4851.96 (Apr. 2026 ) = MXN26,414 Mil.
Agilent Technologies's Cash Flow from Investing for the trailing twelve months (TTM) ended in Apr. 2026 was -1804.512 (Jul. 2025 ) + -1669.185 (Oct. 2025 ) + -1613.485 (Jan. 2026 ) + -1348.74 (Apr. 2026 ) = MXN-6,436 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agilent Technologies (MEX:A) has a Sloan Ratio % of 2.45% as of Apr. 2026. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Agilent Technologies and its competitors.
Is Agilent Technologies' Sloan Ratio % too high?
Agilent Technologies' current Sloan Ratio % is 2.45%. Overall, Agilent Technologies has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Sloan Ratio % compare to NTRA and WAT?
Agilent Technologies' Sloan Ratio % of 2.45% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Medical Diagnostics & Research company?
A good Sloan Ratio % depends on the Medical Diagnostics & Research industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current Sloan Ratio % is 2.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (MEX:A) is currently considered Fairly Valued. The stock's GF Value™ is MXN2,483.83, compared to a current price of MXN2,350.00 — trading 5.4% below its estimated fair value. The current Sloan Ratio % is 2.45%. Agilent Technologies' overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Agilent Technologies (MEX:A), the current Sloan Ratio % is 2.45% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (MEX:A) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of MXN2,350.00 is trading 5.4% below its estimated GF Value™ of MXN2,483.83.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for MEX:A:
Sloan Ratio %: 2.45%
GF Value™: MXN2,483.83 vs. price of MXN2,350.00 (5.4% below fair value)
No single metric tells the full story. See the MEX:A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
91GF Score
Get the complete analysis for MEX:A
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:A has been successfully added to your 
